Given that HMGB1 has been reported to deteriorate neurovascular complications in stroke and might be elevated after tPA treatment evidenced in our present study, preventing HMGB1 signaling might provide a good strategy to attenuate the side effects caused by tPA. This evidence concerns the gene HMGB1 and Stroke.